Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

CytoMed Therapeutics Ltd

GDTC ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$0.97

▼ -4.46%

Market Cap $11.83M · Vol 6.94K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$11.83M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

60.45

Momentum

Beta

-0.09

vs Market

52W High

$3.66

73.63% below

52W Low

$0.71

35.86% above

Volume

6.94K

Avg 17.37K

P/B

3.10

Price-to-book

ROE

N/A

Return on equity

Free Float

29.53%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, CytoMed Therapeutics Ltd (GDTC) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GDTC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+7.51%

-2.52%

-14.60%

-7.21%

YTD

-27.44%

-46.98%

-72.35%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$252.35K
Net Income	$-3,108,783.00
Revenue Growth (YoY)	+142.44%
Gross Margin	25.10%
Operating Margin	-1,307.60%
Net Profit Margin	-1,231.97%
ROE	N/A
ROA · ROIC	-44.27% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	61.62
P/B	3.10
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	11.83M

Technical Indicators

50-Day SMA	$0.96
200-Day SMA	$1.16
RSI (14)	60.45
Beta	-0.09
52-Week High	$3.66
52-Week Low	$0.71

Volume Today	6.94K
Avg Daily Volume (30D)	17.37K
Relative Volume	0.40x
Volatility (10D)	105.56
Volatility (30D)	112.89
Free Float	29.53%

Analyst Consensus

N/A

Current Price $0.97

Mean Target N/A

52W Low$0.71 52W High$3.66

Current

Target

$0.71 $3.66

Current Analyst target

· 0 analysts

Identifiers

ExchangeNasdaq

FIGIBBG01BM32GN0

ISINSGXZ17669631

CountrySingapore

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -3.94% ARGX.BR argenx SE -4.19% ARGX argenx SE -2.76% INSM Insmed Inc -1.42% 2269.HK WuXi Biologics (Cayman) Inc -4.71%

Company Profile

CytoMed Therapeutics Limited is a biopharmaceutical company. It is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT, and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The Company also has the allogeneic gamma delta T cell technology, namely TCB-002.